Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs GSK plc — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5, while GSK plc trades at $50.58 (market cap $104.15B). The key difference: GSK plc pays a 3.48% dividend while State Street SPDR Bloomberg 1-3 Month T-Bill ETF pays none. Which is the better fit depends on your goals.
| BIL | GSK | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $61.18 |
52-Week Low | $91.27 | $38.22 |
Market Cap | — | $104.15B |
Enterprise Value | — | $124.56B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIL trades at $91.48 with minimal daily movement (+0.03%), showing stability amid market volatility. The ETF maintains consistent dividend distributions of $0.27 per share quarterly, with recent institutional buying activity indicating professional confidence. Technical indicators show bearish momentum with moving averages signaling caution, though oscillators suggest potential stabilization near current levels.
As a short-term Treasury ETF, BIL offers capital preservation and steady income through Treasury bill exposure. Key risks include interest rate sensitivity and inflation pressures affecting Treasury yields. The fund's defensive positioning appeals to risk-averse investors seeking liquidity and minimal credit risk in uncertain markets.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
